Helix BioPharma Company Description
Helix BioPharma Corp. operates as an immune-oncology company in Canada.
Its product pipeline comprises L-DOS47, for the treatment of non-small cell lung cancer; LDOS001, which is in phase I clinical trial to treat non-small cell lung cancer; LDOS002, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer; LDOS003, which is in phase II clinical trial to treat non-small cell lung cancer; LDOS006, which is in phase Ib/II for the treatment of pancreatic cancer.
It develops V-DOS47, an antibody-DOS47 conjugate that targets the vascular endothelial growth factor 2 receptor.
It has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging.
Helix BioPharma Corp. was incorporated in 2008 and is headquartered in Vancouver, Canada.
| Country | Canada |
| Founded | 2008 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Jacek Antas |
Contact Details
Address: 1055 West Georgia Street Vancouver, V6E 3P3 Canada | |
| Website | helixbiopharma.com |
Stock Details
| Ticker Symbol | HBPCF |
| Exchange | OTCMKTS |
| Fiscal Year | August - July |
| Reporting Currency | CAD |
| ISIN Number | CA4229101098 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jacek Antas | Chief Executive Officer |
| James Murphy | Chief Financial Officer |